Basit öğe kaydını göster

dc.contributor.authorDedeoğlu, Bala Gür
dc.contributor.otherNoyan, Senem
dc.contributor.otherGürdal, Hakan
dc.date.accessioned2020-05-08T12:30:22Z
dc.date.available2020-05-08T12:30:22Z
dc.date.issued2019
dc.identifier.othere0215894tr_TR
dc.identifier.urihttps://doi.org/10.1371/journal.pone.0215894tr_TR
dc.identifier.urihttp://hdl.handle.net/20.500.12575/71238
dc.description.abstractmiRNAs may play effective roles in breast cancer so modulating their expression levels could have therapeutic benefits. Recent studies have found the combination of miRNA-based therapeutics with conventional drugs as promising. This study aimed to find drug-responsive miRNAs, and explore their anticancer activities in HER2+ breast cancer cells and regulatory role in the trastuzumab response. qRT-PCR-array analysis was performed with effective concentrations of tamoxifen and trastuzumab treated BT-474, SK-BR-3 and MCF-7 cells. Motility and invasion analyses were performed with wound healing and xCELLigence impedance-based assays respectively. Viability of cells following mimic transfection and drug treatment was assessed by WST-1 assay. Western blot analysis was used to assess miR-770-5p regulation of proteins and their phosphorylated forms. The clinical relevance of miR-770-5p was examined by TCGA data analysis. The qRT-PCR-array results indicated that miR-770-5p was responsive in a drug and cell line independent manner. Over-expression of miR-770-5p inhibited the motility and cell invasion through regulation of AKT and ERK proteins. Additionally, miR-770-5p potentiated the effectiveness of trastuzumab. Thus, regulating the expression level of miR-770-5p in combination with trastuzumab treatment may simultaneously inhibit the downstream elements of PI3K and MAPK signalling, thereby blocking the proliferation, motility and invasion capacities of HER2+ breast cancer cells. © 2019 Noyan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.tr_TR
dc.language.isoentr_TR
dc.relation.isversionof10.1371/journal.pone.0215894tr_TR
dc.subjectBreast Neoplasmstr_TR
dc.subjectReceptortr_TR
dc.titleInvolvement of miR-770-5p in trastuzumab response in HER2 positive breast cancer cellstr_TR
dc.typeArticletr_TR
dc.relation.journalPLoS ONEtr_TR
dc.contributor.departmentBiyoteknoloji Enstitüsütr_TR
dc.identifier.volume14tr_TR
dc.identifier.issue4tr_TR
dc.identifier.startpage01tr_TR
dc.identifier.endpage14tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıtr_TR
dc.description.indexPubmed


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster